Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation

JE Shook, PK Lemcke, CA Gehrig, VJ Hruby and TF Burks

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson.

We evaluated the ability of mu [morphine, Tyr-Pro-N-MePhe-D-Pro-NH2 (PLO17)], delta (Tyr-D-Pen-Gly-Phe-D-Pen) (DPDPE) and kappa [U50,488H, (trans-3,4-dichloro-N-methyl-N-(2-(1-pyr-rolidinyl) cyclo- hexyl)benzeneacetamine)] opioid receptor selective agonists to inhibit diarrhea induced by castor oil (0.6 ml p.o.) in mice after supraspinal (i.c.v.) and peripheral (s.c.) administration. The antidiarrheal potency of each compound was compared to its analgesic and gastrointestinal antitransit potency when given by the same route of administration. When administered i.c.v., morphine, PLO17 and DPDPE inhibited diarrhea in a dose-related fashion. The mu agonists, morphine and PLO17, given i.c.v, inhibited diarrhea at doses much lower than those needed to produce analgesia or to inhibit gastrointestinal transit. DPDPE (i.c.v.) was equipotent in inhibiting diarrhea and in eliciting analgesia, but did not effect the rate of transit. U50,488H (i.c.v.) inhibited diarrhea only at extremely high doses which also caused profound postural-motor incapacitance. U50,488H given i.c.v. had no effect on transit at any dose. When given peripherally, morphine, PLO17, DPDPE and U50,488H all inhibited diarrhea in a dose-related fashion. All four compounds inhibited diarrhea at doses much below those needed to cause analgesia. Morphine s.c. and PLO17 s.c. both inhibited diarrhea at doses lower than those required to inhibit transit. DPDPE s.c. and U50,488H s.c. had no effect on transit at any dose. The antidiarrheal effects of i.c.v. morphine, i.c.v. PLO17 and i.c.v. DPDPE were antagonized by pretreatment with 1 microgram i.c.v. of naltrexone.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 249, Issue 1, pp. 83-90, 04/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. M. Raehal, J. K. L. Walker, and L. M. Bohn Morphine Side Effects in {beta}-Arrestin 2 Knockout Mice J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1195 - 1201. [Abstract] [Full Text] [PDF]

				M. Bennett and H. Cresswell Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning Palliative Medicine, July 1, 2003; 17(5): 418 - 422. [Abstract] [PDF]

				S. N. Sterious and E. A. Walker Potency Differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an Antagonist of Peptide and Alkaloid {micro}-Agonists in an Antinociception Assay J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 301 - 309. [Abstract] [Full Text] [PDF]

				L. Valle, O. Pol, and M. M. Puig Intestinal Inflammation Enhances the Inhibitory Effects of Opioids on Intestinal Permeability in Mice J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 378 - 387. [Abstract] [Full Text]

				M. M. Puig and O. Pol Peripheral Effects of Opioids in a Model of Chronic Intestinal Inflammation in Mice J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1068 - 1075. [Abstract] [Full Text]